Virtual Screening

Virtual screening ranks a library of candidate molecules for a target. In structure-based workflows, ranking may use docking poses, scoring functions, learned affinity models, or filters.

Given a target pocket and a molecule library , a simple screening objective is:

where is the generated or selected pose for ligand , and is a scoring function.

Enrichment at top can be written as:

Screening Contract

Virtual screening is a ranking task over a specific candidate pool:

where is a ligand candidate, is its prepared representation, and is activity or relevance metadata when available.

For a reusable note, state:

FieldQuestion
target contextprotein, pocket, receptor state, cofactors, waters, and assay context
library sourceknown actives, measured inactives, decoys, purchasable library, generated set, or public benchmark
ligand preparationstandardization, protonation, tautomer, stereochemistry, conformers
pose policydocked pose, known pose, generated pose, ensemble, or no pose
scoring policydocking score, learned score, consensus, filter, or reranker
denominatorall attempted compounds, successfully docked compounds, or post-filtered compounds

The denominator is part of the claim. Reporting only post-filtered molecules can overstate practical screening quality.

Ranking Pipeline

A structure-based screening workflow is often:

Each arrow can fail. A paper should separate ligand preparation failure, pose generation failure, scoring failure, and final ranking quality.

Metrics

Use ranking metrics that match the screen:

MetricUseMain Caveat
EF@K or EF at top fractionearly active enrichmentsensitive to active prevalence and decoys
ROC-AUCglobal ranking over positives/negativescan look good while early enrichment is weak
BEDROC or early-recognition metrictop-heavy rankingparameter choice affects interpretation
precision@Kfixed wet-lab or compute budgetdepends on candidate pool and label completeness
hit rate after filterspractical pipeline yielddenominator must include failed candidates

For docking-based screens, pose plausibility and enrichment should be reported separately.

Checks

  • Is the library filtered for chemistry, duplicates, and assay compatibility?
  • Are decoys realistic, or do they make the task artificially easy?
  • Is ranking driven by pose quality, affinity, ligand bias, or dataset artifacts?
  • Are top-ranked molecules inspected for validity and novelty?
  • Are negative sets and applicability domain reported?
  • Is pose generation failure separated from scoring failure?
  • Is early enrichment reported instead of only global classification metrics?
  • Are failed, invalid, or filtered molecules included in sample accounting?
  • Is the target split new protein, new ligand scaffold, new pair, or within-family interpolation?